What is Zacks Research’s Estimate for ACAD Q1 Earnings?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Equities researchers at Zacks Research decreased their Q1 2025 EPS estimates for shares of ACADIA Pharmaceuticals in a research report issued to clients and investors on Tuesday, March 18th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will earn $0.09 per share for the quarter, down from their prior estimate of $0.14. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share. Zacks Research also issued estimates for ACADIA Pharmaceuticals’ Q4 2025 earnings at $0.19 EPS, FY2025 earnings at $0.68 EPS, Q1 2026 earnings at $0.10 EPS, Q2 2026 earnings at $0.26 EPS, Q3 2026 earnings at $0.32 EPS, Q4 2026 earnings at $0.33 EPS, FY2026 earnings at $1.01 EPS and FY2027 earnings at $1.37 EPS.

ACAD has been the subject of a number of other research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. Guggenheim downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the company from $23.00 to $20.00 in a report on Friday, January 3rd. Deutsche Bank Aktiengesellschaft started coverage on shares of ACADIA Pharmaceuticals in a report on Tuesday, February 11th. They issued a “hold” rating and a $22.00 price target for the company. StockNews.com upgraded shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, March 8th. Finally, Morgan Stanley restated an “equal weight” rating and set a $20.00 target price on shares of ACADIA Pharmaceuticals in a report on Friday, March 7th. Eight research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, ACADIA Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $24.00.

ACADIA Pharmaceuticals Stock Performance

Shares of ACADIA Pharmaceuticals stock opened at $17.29 on Thursday. The company has a market cap of $2.88 billion, a P/E ratio of 22.17 and a beta of 0.43. ACADIA Pharmaceuticals has a one year low of $14.15 and a one year high of $20.68. The firm has a fifty day moving average of $18.39 and a two-hundred day moving average of $17.00.

Insider Buying and Selling

In related news, Director Elizabeth A. Garofalo sold 4,919 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $18.23, for a total value of $89,673.37. Following the transaction, the director now owns 17,595 shares in the company, valued at approximately $320,756.85. This trade represents a 21.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last three months, insiders have sold 6,167 shares of company stock valued at $114,583. Insiders own 28.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Summit Investment Advisors Inc. raised its holdings in ACADIA Pharmaceuticals by 6.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 12,519 shares of the biopharmaceutical company’s stock valued at $230,000 after buying an additional 795 shares during the period. Quest Partners LLC raised its holdings in ACADIA Pharmaceuticals by 42.3% in the third quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock valued at $54,000 after buying an additional 1,047 shares during the period. Arete Wealth Advisors LLC raised its holdings in ACADIA Pharmaceuticals by 15.9% in the fourth quarter. Arete Wealth Advisors LLC now owns 13,700 shares of the biopharmaceutical company’s stock valued at $251,000 after buying an additional 1,875 shares during the period. KBC Group NV raised its holdings in ACADIA Pharmaceuticals by 67.0% in the fourth quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company’s stock valued at $93,000 after buying an additional 2,044 shares during the period. Finally, Virtus Fund Advisers LLC purchased a new position in ACADIA Pharmaceuticals in the fourth quarter valued at approximately $39,000. Hedge funds and other institutional investors own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.